Hesperos: uniting organs on a chip

Hesperos is developing reconfigurable multi-organ chips it thinks could become standard features of IND fillings within five years

Hesperos hopes to supplant animal models as the standard preclinical testing ground by designing reconfigurable, multi-organ chips to predict drug efficacy and toxicity early in development.

The organ-on-a-chip company spun out of the Tissue Chip program at NIH’s National Center for Advancing Translational Sciences (NCATS) in 2014 with the goal of reducing the overall time and cost of drug development, and detecting signals that animal models miss. FDA, NIH and DARPA have pushed to replace animal studies with more predictive preclinical tests, particularly

Read the full 827 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE